Kyverna Therapeutics and ElevateBio to Advance Kyverna's Ingenui-T Cell Therapy Manufacturing
Kyverna to leverage ElevateBio BaseCamp's expertise in process development and cell product manufacturing to achieve a lower cost of goods
Ingenui-T is an optimized autologous CAR-T cell manufacturing process for autoimmune diseases
EMERYVILLE, Calif. and WALTHAM, Mass., Sept. 26, 2023 /PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a clinical-stage cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases and ElevateBio, LLC ("ElevateBio"), a technology-driven company focused on powering transformative cell and gene therapies, today announced a partnership to advance process development and manufacturing to produce industry-leading Ingenui-T-derived chimeric antigen receptor (CAR) T-cell therapies. Ingenui-T is an optimized autologous manufacturing platform developed by Kyverna to specifically address the needs of patients with autoimmune diseases, enabling a lower cost of goods and an improved patient experience.
ElevateBio and Kyverna will implement Kyverna's Ingenui-T platform into their process development and cell product manufacturing efforts at ElevateBio BaseCamp®. BaseCamp is ElevateBio's end-to-end genetic medicine current Good Manufacturing Practice (cGMP) manufacturing and process development business with capabilities for research, clinical, and commercial cell and gene therapies.
Building and improving on the learnings from CAR T-cell therapy in oncology, Kyverna is seeking to revolutionize the way patients with autoimmune diseases are treated. "We are excited by the potential to not only provide dramatic benefit to patients by eliminating the underlying disease pathology using CAR T-cell therapy, but also to bring innovation to other aspects of the patient journey," said Karen Walker, chief technology officer at Kyverna. "Together with ElevateBio, we aim to deliver radical benefits to patients in less time, with lower impact, and at substantially reduced cost."
"At ElevateBio, we have combined multiple next-generation technology platforms with industry-leading expertise to transform the current cell and gene therapy development paradigm," said Michael Paglia, chief operating officer at ElevateBio BaseCamp. "We are delighted to build a long-term relationship with Kyverna to optimize manufacturing processes and accelerate the development of their therapies."
About Kyverna Therapeutics
In addition to enabling a broad breadth of biopharmaceutical companies in the development of their novel cell and gene therapies, ElevateBio is also building a highly innovative pipeline of cellular, genetic, and regenerative medicines. ElevateBio aims to be the dominant engine inside the world's greatest scientific advancements harnessing human cells and genes to alter disease. For more, visit www.elevate.bio or follow ElevateBio on LinkedIn or Twitter.
Kyverna Media Contact:
View original content to download multimedia:https://www.prnewswire.com/news-releases/kyverna-therapeutics-and-elevatebio-to-advance-kyvernas-ingenui-t-cell-therapy-manufacturing-301938127.html
SOURCE Kyverna Therapeutics